Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Pfaffia paniculata* extract, commonly known as Brazilian ginseng or Suma, is a botanical extract derived from the roots of the *Pfaffia paniculata* plant. It is widely utilized as a dietary supplement and adaptogen, intended to enhance the body's resistance to stressors. The extract contains a variety of bioactive compounds, including pfaffic acid, saponins (pfaffosides), and ecdysteroids. Research indicates that the extract possesses significant antioxidant, anti-inflammatory, and antimicrobial properties. Specifically, it has shown in vitro efficacy in inhibiting the growth and biofilm formation of oral pathogens such as *Fusobacterium nucleatum* and *Parvimonas micra*, which are implicated in gut dysbiosis and the progression of colorectal neoplasms. Despite its traditional use and promising preclinical data, it is not currently approved as a pharmaceutical drug for specific clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pfaffia paniculata extract.